Where to buy Mogamulizumab

Mogamulizumab (Mogamulizumab) is a monoclonal antibody drug used to treat specific types of lymphoma, mainly T cell lymphoma.

Moglizumab's primary mechanism of action is to target theCCR4 receptor, a chemokine receptor that is often overexpressed in T cell lymphoma. It is an immunotherapy drug that works in a variety of ways. First, it can directly bind to the CCR4 receptor, thereby blocking the signaling pathway within the receptor and reducing the proliferation and survival of malignant T cells. Secondly, moglizumab can also enhance the anti-tumor effect by activating the body's immune system, prompting natural killer cells (NK cells) and other immune cells to recognize and attack malignant T cells.

Moglizumab has been approved to treat two types of T cell lymphoma, peripheral T-cell lymphoma (Peripheral T-cell lymphoma, PTCL) and skin T cell lymphoma (Cutaneous T-cell lymphoma, CTCL). These diseases are often insensitive to traditional chemotherapy treatments, so moglizumab offers patients a new treatment option.

The efficacy of moglizumab has been verified in multiple clinical trials. Among them, an important trial is the Mogamulizumab versus investigator's choice of chemotherapy in relapsed PTCL (MAVORIC) trial, which recruited adult patients with relapsed PTCL. The results showed that the median progression-free survival in the mogamulizumab treatment group (median progression-free survival, PFS) were significantly better than those in the chemotherapy group, indicating that moglizumab is effective in the treatment of relapsed patients.PTCL has significant efficacy.

Moglizumab is already on the market in China, but it is not covered by medical insurance. Please consult your local hospital pharmacy for specific prices.